Vol. 2 No. 3 (2022)
Reimbursement Recommendations

Tralokinumab (Adtralza)

Published March 23, 2022

Key Messages

  • CADTH recommends that Adtralza should not be reimbursed by public drug plans for the treatment of atopic dermatitis (AD).
  • Evidence from 3 clinical trials showed that after 16 weeks of treatment, Adtralza was only modestly effective in reducing AD symptoms, including eliminating (or almost eliminating) skin lesions, alleviating itchy skin, and improving quality of life. These modest effects were shown when Adtralza was used alone or in combination with a topical corticosteroid.
  • In another clinical trial in patients with severe AD, Adtralza in combination with topical corticosteroids effectively improved the Eczema Area and Severity Index (EASI) score (a tool used to measure the extent and severity of disease), but this effect was modest. In this same study, treatment with Adtralza in combination with topical corticosteroids did not significantly improve itchy skin than placebo in combination with topical corticosteroids.
  • Results from indirect evidence are inconsistent: 1 indirect comparison suggested that Adtralza is less effective than dupilumab, while the indirect evidence submitted by the sponsor suggested that Adtralza (redacted text) dupilumab.
  • There is a need for more treatment options for patients whose AD is not controlled despite the use of existing treatments; however, the evidence reviewed did not show that Adtralza would meet this need.